TRAVERE THERAPEUTICS, INC. Cash and Cash Equivalents
TRAVERE THERAPEUTICS, INC. (TVTX) had Cash and Cash Equivalents of $117.73 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-04
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $117.73M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $78.36M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $93.03M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $110.93M.
| Period end | Cash and Cash Equivalents, at Carrying Value | Cash and Cash Equivalents, at Carrying Value as first filed |
|---|---|---|
| 2026-06-30 | $117.73M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $78.36M 10-Q · filed 2026-05-04 | |
| 2025-12-31 | $93.03M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $110.93M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $75.15M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $61.90M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $58.53M 10-K · filed 2026-02-19 | |
| 2024-09-30 | $36.41M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $32.29M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $43.25M 10-Q · filed 2024-05-06 | |
| 2023-12-31 | $58.18M 10-K · filed 2025-02-21 | |
| 2023-09-30 | $144.24M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $70.87M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $161.38M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $61.69M 10-K · filed 2024-02-20 | |
| 2022-09-30 | $151.34M 10-Q · filed 2022-10-27 | |
| 2022-06-30 | $179.76M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $256.57M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $165.75M 10-K · filed 2023-02-23 | |
| 2021-09-30 | $150.33M 10-Q · filed 2021-10-29 | |
| 2021-06-30 | $83.29M 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $148.23M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $84.77M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $200.48M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $237.17M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $67.02M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $62.44M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $65.19M 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $75.66M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $69.84M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $102.87M 10-K · filed 2020-02-24 | |
| 2018-09-30 | $154.82M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $89.31M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | $61.12M 10-Q · filed 2018-07-06 | |
| 2017-12-31 | $99.39M 10-K · filed 2019-02-26 | |
| 2017-09-30 | $98.99M 10-Q · filed 2018-11-01 | |
| 2017-06-30 | $89.27M 10-Q · filed 2018-08-03 | $89.27M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $41.87M 10-Q · filed 2018-07-06 | $41.87M 10-Q · filed 2017-05-05 |
| 2016-12-31 | $41.00M 10-K · filed 2019-02-26 | |
| 2016-09-30 | $23.89M 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $21.16M 10-Q · filed 2017-08-09 | |
| 2016-03-31 | $23.26M 10-Q · filed 2017-05-05 | |
| 2015-12-31 | $37.80M 10-K · filed 2019-02-26 | |
| 2015-09-30 | $140.60M 10-Q · filed 2016-11-04 | |
| 2015-06-30 | $127.75M 10-Q · filed 2016-08-05 | |
| 2015-03-31 | $120.17M 10-Q · filed 2016-05-05 | $120.17M 10-Q · filed 2015-05-11 |
| 2014-12-31 | $18.20M 10-K · filed 2018-07-06 | $18.20M 10-K · filed 2015-03-11 |
| 2014-09-30 | $25.86M 10-Q · filed 2015-11-06 | $25.86M 10-Q · filed 2014-11-13 |
| 2014-06-30 | $39.88M 10-Q · filed 2015-08-10 | $39.88M 10-Q · filed 2014-08-14 |
| 2014-03-31 | $3.70M 10-Q · filed 2015-05-11 | |
| 2013-12-31 | $6.00M 10-K · filed 2017-03-01 | $6.00M 10-K · filed 2014-03-28 |
| 2013-09-30 | $13.41M 10-Q/A · filed 2015-07-09 | |
| 2013-06-30 | $286.51K 10-Q · filed 2014-08-14 | |
| 2013-03-31 | $2.50M 10-Q · filed 2014-05-15 | |
| 2012-12-31 | $11.00K 10-K · filed 2016-02-26 | $11.39K 10-K · filed 2013-06-13 |
| 2012-09-30 | $2.19K 10-Q/A · filed 2015-07-09 | |
| 2012-06-30 | $31.42K 10-Q · filed 2013-09-16 | |
| 2012-03-31 | $1.29K 10-Q/A · filed 2013-09-16 | |
| 2011-12-31 | $10.05K 10-Q/A · filed 2015-07-09 | |
| 2011-03-10 | $0.00 10-Q · filed 2013-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |